• Menu
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Before Header

This project has received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement No [820523]

Phagovet

Phagovet

Header Right

 

  • Home
  • The Phagovet Project
  • Work packages – Phagovet | Poultry
  • Partners
  • News and events
  • Contact
  • Home
  • The Phagovet Project
  • Work packages – Phagovet | Poultry
  • Partners
  • News and events
  • Contact
Bacteriophage P479 against multidrug-resistant Escherichia coli

Characterization and genome analysis of a broad lytic spectrum bacteriophage P479 against multidrug-resistant Escherichia coli

January 15, 2022

Broad lytic spectrum bacteriophage P479 against multidrug-resistant Escherichia coli

The increase in antibiotic resistance in pathogens such as E. coli poses a major challenge for the treatment of infections.

Fortunately, bacteriophages offer a promising alternative to combat these resistant strains.

Studies have found that the phage P479 is capable of lysing multiple serotypes and drug-resistant strains of E. coli from avian and human sources. Its one-step growth curve also showed a short latency and large burst size, suggesting its efficacy as a potential treatment option.

In addition, P479 showed good stability under various environmental conditions, making it a viable option for real-world use.

Overall, bacteriophages such as P479 offer hope for combating the threat of antibiotic resistance and treating infections caused by E. coli.


The authors Pei Li, Hui Wang, Min Li, Weiling Qi, Zitai Qi, Weiye Chen, Yongyi Dong, Zhengjun Xu, Wei Zhang published these findings in their article Characterization and genome analysis of a broad lytic spectrum bacteriophage P479 against multidrug-resistant Escherichia coli, dated 15 January 2022.

Key findings:

  • A colipage called P479, found in poultry farm effluent, has the ability to lyse multiple serotypes of E. coli, including avian pathogenic E. coli, enterohemorrhagic E. coli, and neonatal meningitis E. coli
  • P479 is also capable of lysing multi-drug resistant strains of E. coli.
  • The one-step growth curve shows that the latency ofP479 is 10 minutes and the burst size is 318 PFU/cell.
  • Stability tests show thatP479 is stable under various temperature (4 to 50 °C) and pH (3 to 11) conditions
  • Antibacterial activity in vitro shows thatP479 exhibits varying degrees of bacteriostatic activity against different bacteria.

Bacteriophage P479 against multidrug-resistant Escherichia coli
 

Abstract

The increase of multi-drug resistant and multi-serotypes of pathogenic Escherichia coli has brought more severe challenge to control infection.

Nowadays, bacteriophage is a promising tool to treat colibacillosis as an alternative of antibiotics.

A coliphage P479, isolated from sewage of poultry farm, could lyse multiple serotypes, including not only O1, O2, O8, O9, O21, O78, O83, O145 of Avian pathogenic E. coli, but O157:H7 of Enterohaemorrhagic E. coli and O18:K1:H7 Neonatal meningitis E. coli. Additionally, P479 could also lyse multi-drug resistant E. coli. These indicated that P479 had good lytic ability.

One-step growth curve revealed that the latent time period of P479 was 10 min and the burst size was about 318 PFU/cell. Stability tests demonstrated that P479 had good stability under various temperature (4 to 50 °C) and pH (3 to11) conditions. P479 contained of a linear, double-stranded DNA molecule of 172,033 bp with 40.3% GC content.

P479 contained 296 putative coding sequences (CDSs) and two tRNA genes.

Based on genomic comparison, P479 was classified as a member of genus Gaprivervirus, subfamily Tevenvirinae, family Myoviridae, order Caudovirales.

No known virulent or lysogenic genes were detected in the genome of P479, manifesting P479 was safe to adhibit.

Antibacterial activity in vitro manifested that P479 has varying degrees bacteriostatic activity against different bacteria.

According to the above properties, P479 has the potential to be applied in phage therapy in the future.

Keywords: Bacteriophage; Broad lytic spectrum; E. coli; Genome sequencing; Multiple drug resistance; Serotypes.

Copyright © 2021 Elsevier B.V. All rights reserved.


 

Previous Post: «Phages faqs photo Phages: commonly asked questions
Next Post: Characterization of Clostridium perfringens bacteriophages and their application in chicken meat and milk Clostridium perfringens bacteriophages and their application in chicken meat and milk»

Primary Sidebar

Categories

  • Events
  • News
  • Scientific article
  • Uncategorised

Follow us on LinkedIN

Latest news

Role of Bacteriophages for Optimized Health and Production of Poultry

Bacteriophages and the production of poultry The poultry sector has …

Anti-Salmonella polyvinyl alcohol coating containing a virulent phage PBSE191 and its application on chicken eggshell

Anti-Salmonella polyvinyl alcohol coating - phage PBSE191 Antibiotic …

Characterization and Genomic Analysis of Escherichia coli O157:H7 Phage UAE_MI-01 Isolated from Birds

Genomic Analysis of Escherichia coli O157:H7 - Phages Escherichia coli …

Endolysins of bacteriophage vB_Sal-S-S10 can naturally lyse Salmonella enteritidis

Bacteriophage - Salmonella enteritidis The holin-endolysin lysis system …

Examining the effects of Salmonella phage on the caecal microbiota and metabolome features in Salmonella-free broilers

Salmonella phages Bacteriophages, or phages, are viruses that can infect …

Footer

Partners

  • ALS Life Sciences
  • CECAV
  • UAB
  • VETWORKS

Navigate

  • Home
  • The Phagovet Project
  • Work packages – Phagovet | Poultry
  • Partners
  • News and events
  • Contact

Copyright © 2023 · Phagovet EU | Privacy statement